 NEW YORK, May 03, 2021 GLOBE NEWSWIRE -- Intra-Cellular Therapies, Inc. Nasdaq: ITCI, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system CNS disorders, today announced that the U.S. Food and Drug Administration FDA has accepted for review its supplemental New Drug Applications sNDAs for lumateperone, an investigational agent for the treatment of depressive episodes associated with bipolar I or II disorder bipolar depression as monotherapy and as adjunctive therapy with lithium or valproate. The FDA has assigned a Prescription Drug User Fee Act PDUFA target action date of December 17, 2021 for the applications. If approved, CAPLYTA has the potential to be an important medicine for a broad group of patients suffering from these highly prevalent, chronic complex conditions. 